Bucinnazine
Clinical data | |
---|---|
Other names | AP-237 |
Legal status | |
Legal status |
|
Identifiers | |
| |
JSmol) | |
| |
|
Bucinnazine (AP-237, 1-butyryl-4-cinnamylpiperazine) is an opioid analgesic drug that was widely used in China to treat pain in cancer patients as of 1986.[2] It is one of the most potent compounds among a series of piperazine-amides first synthesized and reported in Japan in the 1970s.[3][4][5] Bucinnazine has analgesic potency comparable to that of morphine but with a relatively higher therapeutic index.
The drug was initially claimed to be a non-narcotic analgesic. However, subsequent studies have shown bucinnazine and similar acyl piperazines to be potent and selective
Derivatives
2-methyl-AP-237 has been sold on the grey market as a designer opioid, first identified by a police forensic laboratory in Slovenia in March 2019.[7][8][9] In 2023, the United States Department of Justice took criminal action against two individuals for selling 2-methyl-AP-237 under the false pretenses that such product was intended for 'research purposes' only. One of the pair was sentenced to five years in federal prison.[10]
See also
References
- ^ "2-Methyl-AP-237" (PDF). Office of Diversion Control. U.S Drug Enforcement Administration.
- ^ a b Qing T, Zhi-Ji C, Wei-Ping W (1986). "Experimental Study on the Dependence-Producing Properties of Qiang Tong Ding (AP-237)". Chin. J. Clin. Pharmacol. (2).
- PMID 4916908.
- PMID 1156018.
- PMID 1156016.
- S2CID 23360530.
- ^ "Analytical Report 2-Methyl-AP-237" (PDF). Ljubljana, Slovenia: National Forensic Laboratory. 19 March 2019.
- S2CID 247383361.
- PMID 35918775.
- ^ Affairs Oo (2023-10-30). "New Braunfels Man Sentenced to Five Years in Prison for Selling Misbranded Drugs". DOJ.